Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,231 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,680 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02828878 | Prevention of Acute Graft Versus Host Disease in Patients Undergoing Allogeneic ApoGraft Stem Cell Transplantation | unknown | Phase 1 / Phase 2 | 12 | Cellect BiotechnologyINDUSTRY | 1 | Nov 26, 2019 | clinicaltrials |
| NCT04173455 | Study of the Safety, Tolerability and Pharmacokinetics of HZ-A-018 in Patients With B Cell Lymphoma | unknown | Phase 1 | 46 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Nov 22, 2019 |
| NCT04026100 | CTA101 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma | unknown | Phase 1 | 9 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Oct 31, 2019 | clinicaltrials |
| NCT03836690 | Transfer of Effector Memory T Cells (Tem) Following Allogeneic Stem Cell Transplantation(ToTem) | unknown | Phase 1 | 18 | University College, LondonOTHER | 1 | Oct 25, 2019 | clinicaltrials |
| NCT02836834 | Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of an Anti-PD-1 mAb for Patients With Advanced Solid Tumors | unknown | Phase 1 | 33 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Oct 22, 2019 | clinicaltrials |
| NCT02809092 | Interleukin-21 (IL-21)- Expanded Natural Killer Cells for Induction of Acute Myeloid Leukemia | unknown | Phase 1 / Phase 2 | 30 | Hospital de Clinicas de Porto AlegreOTHER | 1 | Oct 15, 2019 | clinicaltrials |
| NCT03018405 | A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications(THINK) | unknown | Phase 1 / Phase 2 | 146 | Celyad Oncology SAINDUSTRY | 2 | Sep 19, 2019 | clinicaltrials |
| NCT03618602 | Safety, Pharmacokinetics and Efficacy Study of Bisthianostat in Refractory or Recurrent Multiple Myeloma Patients | unknown | Phase 1 | 30 | Shanghai Theorion Pharmaceutical Co Ltd.INDUSTRY | 1 | Sep 19, 2019 | clinicaltrials |
| NCT03497533 | Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With TriCAR-T_CD19(Trident19-H) | unknown | Phase 1 / Phase 2 | 6 | Timmune Biotech Inc.INDUSTRY | 1 | Sep 6, 2019 | clinicaltrials |
| NCT03991559 | A Safety Study of the Pan-immunotherapy in Patients With Unresectable/Metastatic Solid Tumors or Lymphomas | unknown | Phase 1 | 20 | Chinese PLA General HospitalOTHER | 1 | Aug 28, 2019 | clinicaltrials |
| NCT04056975 | Study of A-319 in Patients With Relapsed or Refractory B-cell Lymphoma(A-319) | unknown | Phase 1 | 54 | EVIVE BiotechnologyINDUSTRY | 0 | Aug 14, 2019 | clinicaltrials |
| NCT04007978 | Anti-CD22 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy for Relapsed Refractory B-cell Malignancies | unknown | Phase 1 | 50 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Aug 7, 2019 | clinicaltrials |
| NCT04008251 | Humanized CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies | unknown | Phase 1 | 10 | Wuhan Sian Medical Technology Co., LtdINDUSTRY | 1 | Aug 7, 2019 | clinicaltrials |
| NCT04008381 | Ex-vivo Expanded γδ T Lymphocytes in Patients With Refractory/Relapsed Acute Myeloid Leukaemia | unknown | Phase 1 | 38 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Aug 7, 2019 | clinicaltrials |
| NCT04008394 | Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies | unknown | Phase 1 | 50 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Aug 7, 2019 | clinicaltrials |
| NCT04037566 | CRISPR (HPK1) Edited CD19-specific CAR-T Cells (XYF19 CAR-T Cells) for CD19+ Leukemia or Lymphoma. | unknown | Phase 1 | 40 | Xijing HospitalOTHER | 1 | Jul 30, 2019 | clinicaltrials |
| NCT03913312 | Decitabine Combined With Unrelated Cord Blood Transplantation for Elderly Patients With AML | unknown | Phase 1 / Phase 2 | 150 | Ruijin HospitalOTHER | 1 | Jul 23, 2019 | clinicaltrials |
| NCT04026269 | Clinical Efficacy of MOAP Regimen for Relapsed/Refractory cHL as a Rescue Therapy After DP Regimen | unknown | Phase 1 / Phase 2 | 30 | Han weidongOTHER | 1 | Jul 19, 2019 | clinicaltrials |
| NCT01211457 | Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) | unknown | Phase 1 / Phase 2 | 65 | Cyclacel Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 16, 2019 | clinicaltrials |
| NCT03344367 | Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory B-cell Non-Hodgkin Lymphoma | unknown | Phase 1 | 20 | Peking UniversityOTHER | 1 | Jul 12, 2019 | clinicaltrials |
| NCT03355859 | Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory B-cell Non-Hodgkin Lymphoma | unknown | Phase 1 | 10 | Zhao WeiliOTHER | 1 | Jul 12, 2019 | clinicaltrials |
| NCT04012879 | Study Evaluating the Efficacy and Safety With CD19CAR-T for Relapsed or Refractory Acute Lymphoblastic Leukemia | unknown | Phase 1 | 12 | Chinese PLA General HospitalOTHER | 1 | Jul 9, 2019 | clinicaltrials |
| NCT04012892 | Study Evaluating the Efficacy and Safety With CD19CAR-T for Relapsed or Refractory Non-Hodgkin Lymphoma | unknown | Phase 1 | 12 | Chinese PLA General HospitalOTHER | 1 | Jul 9, 2019 | clinicaltrials |
| NCT03815383 | A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma | unknown | Phase 1 | 12 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 5, 2019 | clinicaltrials |
| NCT03999697 | A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies | unknown | Phase 1 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Jun 27, 2019 | clinicaltrials |
| NCT02349698 | A Clinical Research of CAR T Cells Targeting CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 45 | Southwest Hospital, ChinaOTHER | 1 | Jun 25, 2019 | clinicaltrials |
| NCT02710149 | A Clinical Research of CD20-Targeted CAR-T in B Cell Malignancies | unknown | Phase 1 / Phase 2 | 45 | Southwest Hospital, ChinaOTHER | 1 | Jun 25, 2019 | clinicaltrials |
| NCT02935153 | A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies | unknown | Phase 1 / Phase 2 | 45 | Southwest Hospital, ChinaOTHER | 1 | Jun 25, 2019 | clinicaltrials |
| NCT02937103 | A Clinical Research of CD123-Targeted CAR-T in Myeloid Malignancies | unknown | Phase 1 / Phase 2 | 45 | Southwest Hospital, ChinaOTHER | 1 | Jun 25, 2019 | clinicaltrials |
| NCT02954445 | A Clinical Research of BCMA-Targeted CAR-T in B Cell Malignancies | unknown | Phase 1 / Phase 2 | 45 | Southwest Hospital, ChinaOTHER | 1 | Jun 25, 2019 | clinicaltrials |
| NCT02958410 | A Clinical Research of CD30-Targeted CAR-T in Lymphocyte Malignancies | unknown | Phase 1 / Phase 2 | 45 | Southwest Hospital, ChinaOTHER | 1 | Jun 25, 2019 | clinicaltrials |
| NCT03751293 | A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma | unknown | Phase 1 | 10 | Hebei Yanda Ludaopei HospitalOTHER | 1 | May 15, 2019 | clinicaltrials |
| NCT02965092 | CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies | unknown | Phase 1 / Phase 2 | 80 | Wuhan Sian Medical Technology Co., LtdINDUSTRY | 1 | May 10, 2019 | clinicaltrials |
| NCT03366350 | Anti-CD19 CAR-T Therapy Bridging to HSCT for CD19+ B-Cell Malignancies | unknown | Phase 1 / Phase 2 | 50 | Wuhan Sian Medical Technology Co., LtdINDUSTRY | 1 | May 10, 2019 | clinicaltrials |
| NCT03940833 | Clinical Research of Adoptive BCMA CAR-NK Cells on Relapse/Refractory MM | unknown | Phase 1 / Phase 2 | 20 | Asclepius Technology Company Group (Suzhou) Co., Ltd.INDUSTRY | 1 | May 7, 2019 | clinicaltrials |
| NCT03932955 | MC-19PD1 CAR-T in Relapsed or Refractory B Cell Lymphoma | unknown | Phase 1 | 15 | Peking UniversityOTHER | 1 | May 1, 2019 | clinicaltrials |
| NCT03588598 | Safety, Tolerability, and Pharmacokinetics of SHC014748M in Patients With Indolent B-Cell Hematologic Malignancies | unknown | Phase 1 | 40 | Nanjing Sanhome Pharmaceutical, Co., Ltd.INDUSTRY | 1 | Apr 30, 2019 | clinicaltrials |
| NCT03185494 | Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22 | unknown | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Apr 17, 2019 | clinicaltrials |
| NCT02123836 | Natural Killer Cells in Acute Leukaemia and Myelodysplastic Syndrome | unknown | Phase 1 | 20 | National University Hospital, SingaporeOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT02310243 | Study of Palbociclib in MLL-rearranged Acute Leukemias | unknown | Phase 1 / Phase 2 | 50 | University of UlmOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT03881761 | CD19/20 Bispecific Nanobody-derived CAR-T Cells in B Cell Lymphoma | unknown | Phase 1 | 50 | Henan Cancer HospitalOTHER_GOV | 1 | Mar 21, 2019 | clinicaltrials |
| NCT03881774 | Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell Malignancies | unknown | Phase 1 | 20 | Henan Cancer HospitalOTHER_GOV | 1 | Mar 21, 2019 | clinicaltrials |
| NCT03348033 | Safety and Feasibility of the Use of Natural Killer Cells in Patients With Chronic Myeloid Leukemia | unknown | Phase 1 / Phase 2 | 5 | Hospital de Clinicas de Porto AlegreOTHER | 1 | Mar 12, 2019 | clinicaltrials |
| NCT02652910 | Memory-enriched CAR-T Cells Immunotherapy for B Cell Lymphoma(MeCAR) | unknown | Phase 1 / Phase 2 | 20 | Xinqiao Hospital of ChongqingOTHER | 1 | Feb 27, 2019 | clinicaltrials |
| NCT03093168 | BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple Myeloma | unknown | Phase 1 | 10 | The Second Affiliated Hospital of Henan University of Traditional Chinese MedicineOTHER | 1 | Feb 27, 2019 | clinicaltrials |
| NCT03599375 | Immunotherapy With CD19 CART-cells for B Cell Acute Lymphoblastic Leukemia | unknown | Phase 1 | 20 | jiuwei cuiOTHER | 0 | Feb 26, 2019 | clinicaltrials |
| NCT03854994 | CD19 CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia | unknown | Phase 1 | 10 | Yan'an Affiliated Hospital of Kunming Medical UniversityOTHER | 1 | Feb 26, 2019 | clinicaltrials |
| NCT02799550 | Allogeneic CART-19 for Elderly Relapsed/Refractory CD19+ ALL | unknown | Phase 1 | 10 | The Affiliated Hospital of the Chinese Academy of Military Medical SciencesOTHER | 1 | Feb 25, 2019 | clinicaltrials |
| NCT02842138 | Autologous CD19 CAR T Cells in Relapsed or Refractory B-cell Lymphoma | unknown | Phase 1 | 25 | Peking UniversityOTHER | 1 | Feb 25, 2019 | clinicaltrials |
| NCT03060850 | A Phase I Study of AC0010 in Patients With CLL/ SLL, MCL, DLBCL and Other NHL | unknown | Phase 1 | 184 | Hangzhou ACEA Pharmaceutical Research Co., Ltd.INDUSTRY | 1 | Feb 1, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Nov 26, 2019source: clinicaltrials